Compare CWBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | OMER |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | United States |
| Employees | 341 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.3M | 772.8M |
| IPO Year | N/A | 2008 |
| Metric | CWBC | OMER |
|---|---|---|
| Price | $26.89 | $9.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.63 | ★ $32.50 |
| AVG Volume (30 Days) | 578.3K | ★ 2.3M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $17.64 | $233.22 |
| P/E Ratio | ★ $12.13 | $14.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.51 | $3.34 |
| 52 Week High | $27.73 | $17.65 |
| Indicator | CWBC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 68.26 | 40.66 |
| Support Level | $23.38 | $9.12 |
| Resistance Level | N/A | $11.88 |
| Average True Range (ATR) | 0.65 | 0.92 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 73.75 | 62.40 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.